Categories: NewsPharmaceutical

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET

SCOTTSDALE, Ariz., May 04, 2023 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 11, 2023. Journey Medical management will conduct a conference call and audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10178597/f951c8551f. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets eight products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

Staff

Recent Posts

UP Fintech: Profit Hits Record High; Client Assets Reached US$45.9 Billion

NEW YORK, May 30, 2025 /PRNewswire/ -- UP Fintech Holding Limited (NASDAQ: TIGR) ("UP Fintech" or…

2 hours ago

Next Step Healthcare Notifies Individuals of Data Security Incident

WOBURN, Mass., May 29, 2025 /PRNewswire/ -- Next Step Healthcare, LLC ("Next Step") is providing…

8 hours ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

11 hours ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next…

14 hours ago

Care Career, Inc. Acquires Four Leading Healthcare Staffing Firms in Strategic Growth Move

LAS VEGAS, May 29, 2025 /PRNewswire/ -- Care Career, Inc. (www.carecareer.com) today announced it has…

14 hours ago